From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
Currently, the AI in healthcare sector projected to surpass $110 billion by 2030. However, according to Accenture, artificial intelligence could unlock an additional $461 billion in value across healthcare by 2035—on top of a sector already projected to surpass $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are continuing to raise visibility for their AI-powered diagnostic platform, with Ainnova CEO Vinicio Vargas recently featured as a speaker at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia.
The event brought together leading voices in visual health from across Latin America, with discussions focused on advancing patient outcomes through AI innovation. Vargas, who also sits on the board of Ai-nova Acquisition Corp. (AAC), presented Vision AI as a transformative tool to expand access to early diabetic retinopathy screening and reduce preventable blindness throughout the region.
Vargas also highlighted a Q4 2024 alliance with Roche and prepaid‑health‑plan provider Salud 360 that is piloting Vision AI among high‑risk diabetic patients; if successful, the program will be rolled out in the United States, Canada, and Europe through Ai ‑ nova Acquisition Corp. (AAC), which holds worldwide rights to Ainnova's technology portfolio .
This momentum builds on a recent regulatory breakthrough in the U.S. market. Avant and Ainnova recently completed a key pre-submission meeting with the FDA for Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases.
"We're truly excited about this next phase," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists.
The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI. The FDA session offered clear feedback on study design, site selection, and execution strategy—enabling Ainnova and its clinical trial partner, Fortrea, to finalize preparations for U.S.-based trials.
"This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care."
While regulatory efforts advance in the U.S., the company has already launched a groundbreaking chronic care model across Latin America. The program, now live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offers free, walk-in retinal risk assessments—delivering real-time AI results and connecting at-risk patients directly with clinics and specialists.
Over 30% of diabetics develop diabetic retinopathy, a leading cause of preventable blindness. Vision AI offers early, low-cost screening without the need for an ophthalmologist onsite. The model has gained support from pharmacies, insurers, and pharmaceutical partners—demonstrating real traction across the healthcare value chain.
Avant' s role in these efforts continues to grow. Through Ai-nova Acquisition Corp., which it co-founded and structured, Avant maintains global licensing rights to Ainnova's platform and stands to benefit from both U.S. and international commercialization. The Latin American pilot programs are already generating momentum, with U.S. trials positioned to unlock a vastly larger market.
The company is also preparing a standalone venture to house a potential therapeutic candidate for diabetes—bringing leadership, data, and IP into one streamlined structure for diagnostics and treatment alike.
Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers.
A structural simplification may be on the horizon as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech —potentially consolidating all IP, leadership, and commercial rights under one public entity. Such a move would give investors pure-play exposure to this fast-evolving tech stack, while deepening operational alignment between the firms.
Agenus Inc. (NASDAQ: AGEN) has partnered with AI biotech firm Noetik to develop predictive biomarkers for its cancer immunotherapy combo BOT/BAL.
"At Agenus, we are committed to transforming cancer care through scientific innovation and next-generation immunotherapies," said Dr. Garo Armen, Chairman and CEO of Agenus. "This collaboration with Noetik enables us to harness cutting-edge AI to better understand patient biology and tailor treatments more precisely."
By using Noetik's advanced "virtual cell" models trained on massive tumor datasets, the collaboration aims to identify which patients are most likely to benefit from treatment. This could improve clinical trial outcomes and accelerate personalized cancer care using AI-driven insights
Clover Health Investments, Corp. (NASDAQ: CLOV) recently launched a new pharmacy pilot program across New Jersey in partnership with IPC's iCare+ network. The initiative enables local pharmacies to use AI tools and real-time data to help seniors manage medications and reduce hospital visits.
"This is more than a new program—it's a new model for how we support our New Jersey members," said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. "By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong."
It's part of Clover's strategy to deliver more personal, community-based healthcare while supporting independent pharmacies
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered a definitive agreement to acquire
Monogram Technologies Inc. (NASDAQ: MGRM) for approximately US$177 million in cash, with additional milestone-based payments up to US$12.37 per share.
" Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons – now and into the future. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery."
The acquisition adds Monogram's semi- and fully autonomous orthopedic robotics to Zimmer Biomet's ROSA® platform, aiming to create the most comprehensive robotics suite in the orthopedic space. Monogram's FDA-cleared knee arthroplasty robot is expected to commercialize in 2027, with a fully autonomous version in development.
"Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty," said Benjamin Sexson, CEO of Monogram. "We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale."
Zimmer Biomet expects the deal to be accretive by 2028, supporting long-term growth in the high-demand surgical robotics market.
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Alphabet Just Gave Nvidia Investors Some Great News
Key Points Alphabet now expects to lay out $85 billion in capital expenditures this year -- up from a previously planned $75 billion -- and expects to further accelerate that spending next year. Alphabet's AI capex will be allocated toward servers, accelerated data center buildouts, and cloud computing infrastructure. Rising AI infrastructure spending from hyperscalers such as Alphabet bodes well for Nvidia and its thriving GPU business. 10 stocks we like better than Nvidia › Over the next several weeks, companies will report financial and operating results for the second quarter of 2025. As usual, technology investors will be focused on one thing: artificial intelligence (AI). "Magnificent Seven" member Alphabet kicked things off earlier this week, reporting robust results across its search, advertising, and cloud computing divisions. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » While Alphabet shareholders should be encouraged by the internet giant's strong performance, I saw Nvidia (NASDAQ: NVDA) as the real winner from the company's second-quarter performance. Let's dig into some of the important moves Alphabet is making and assess how Nvidia is benefiting from them. Alphabet is picking up the pace on AI infrastructure construction During the Q2 earnings call, Alphabet's management updated some details of its financial guidance. Alphabet now plans to spend around $85 billion on capital expenditures (capex) in 2025. Of note, this is a $10 billion increase over the company's prior guidance. And there's more. "Looking out to 2026, we expect a further increase in capex due to the demand we're seeing from customers as well as growth opportunities across the company," said Chief Financial Officer Anat Ashkenazi. Despite its increasingly aggressive spending on AI infrastructure over the last few years, Alphabet has stated that it doesn't plan on slowing down anytime soon. This should be music to Nvidia's ears. GOOGL Capital Expenditures (TTM) data by YCharts. Why is this good for Nvidia? Management consulting juggernaut McKinsey & Company is forecasting that AI infrastructure spending could reach $6.7 trillion by 2030. And its research suggests that almost half of that money will be allocated toward AI hardware for further data center construction. In addition, research from Goldman Sachs and JPMorgan indicates that generative AI could add between $7 trillion and $10 trillion to global gross domestic product in the long run. From a macroeconomic perspective, these secular trends bode well for Nvidia's compute and networking empire. Moreover, I think that Alphabet's decision to bump up its AI infrastructure spending again adds some credibility to those industry forecasts. Alphabet's management specified that it is raising its planned capex in order to accelerate the construction of data centers and position itself to fill the rising demand for capacity on the Google Cloud Platform. Increased spending on network equipment, servers, and cloud infrastructure should lead to rising demand for graphics processing units (GPUs). I see this as a major positive development as Nvidia is still scaling up production of chips made using its latest Blackwell architecture. Considering Nvidia holds an estimated 90% share of the data center GPU market, I see Alphabet's investments in AI infrastructure as a major tailwind for the chip king and further propels the company's momentum over competition in the chip space. Is Nvidia stock a buy right now? With a market cap north of $4.2 trillion, Nvidia is currently the most valuable company in the world. While this might lead one to assume that the stock is expensive, its underlying valuation trends tell a different story. NVDA PE Ratio (Forward) data by YCharts Nvidia currently trades at a forward price-to-earnings (P/E) multiple of 40. While this isn't "cheap" by traditional benchmarks, it is notably lower than the peak levels Nvidia has witnessed during the AI revolution. What makes these dynamics interesting is that Nvidia's growth trajectory is arguably far stronger today than it was 18 months ago when its forward P/E valuation peaked. The company remains at the center of the AI revolution, providing massive amounts of fast parallel-processing power to hyperscalers and accelerating AI workloads. To me, buying Nvidia stock at its current price is a no-brainer, and I see Alphabet's rising AI infrastructure spending as a long-term catalyst that should not be overlooked by growth investors. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
2 hours ago
- Globe and Mail
Why Is Wall Street Obsessed With AI (Artificial Intelligence) Leader Arista Networks?
Key Points Arista Networks is a leading network platform provider. Several Wall Street analysts hiked their price targets on Arista Networks stock in July. Those on Main Street should investigate the company for themselves to see if it aligns with their investing goals. 10 stocks we like better than Arista Networks › We all have preferences. From our favorite movies to favorite places to eat to favorite places to visit, people love what they love. Wall Street is no different. Currently, analysts can't get enough of artificial intelligence (AI) stocks. But of all the AI stocks on the Street's radar, Arista Networks (NYSE: ANET) is one AI name that analysts absolutely love. Let's take a look at the basis for this affection for one of the leading network platform providers. Enthusiasm for Arista Networks has heated up in July While Arista Networks' stock received some upgrades in June, it's during July that Wall Street's enthusiasm has been clearly seen. Here are some of the analysts' more recent actions. JPMorgan boosted its price target to $130 from $117 on July 17. Citigroup hiked its price target to $123 from $112 on July 11. Wolfe Research initiated coverage on Arista Networks and assigned an outperform rating on July 7. According to JPMorgan predicated its new price target on the expectation that cloud spending will be strong in the second half of 2025, while Citigroup based its new price target on a growing Ethernet switching market. Besides Wall Street, Arista Networks is growing increasingly popular with customers. The company's industry-leading switches are in high demand as data centers look to shore up their computing infrastructure to support AI computing. And demand for the company's networking solutions seems unlikely to taper off anytime soon. During its first-quarter 2025 financial report, Arista Networks projected its total addressable market will rise from $41 billion in 2024 to $70 billion in 2028. Is now a good time for Main Street investors to listen to Wall Street? The enthusiasm that Wall Street has for Arista Networks is well warranted, but does that mean investors should rush to buy shares? The answer is a resounding No. Investors must -- as always -- do their own due diligence to see if Arista Networks is right for them, but for AI exposure, it certainly demands consideration. Should you invest $1,000 in Arista Networks right now? Before you buy stock in Arista Networks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arista Networks wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Citigroup is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Scott Levine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Arista Networks and JPMorgan Chase. The Motley Fool has a disclosure policy.
Globe and Mail
2 hours ago
- Globe and Mail
2 Artificial Intelligence (AI) Stocks With High Conviction
Key Points Spending on artificial intelligence could reach an astounding $4.8 trillion by 2033. Nvidia's GPUs are critical for the training and deployment of complex AI models. AI developers want the best cloud infrastructure, and Amazon leads in this area. 10 stocks we like better than Nvidia › Fortunes have been made by investing in artificial intelligence (AI) stocks. But there's still a lot of room left to go. The United Nations, for instance, believes that the AI market will grow from $189 billion worldwide in 2023 to nearly $5 trillion by 2033. Want to make sure your portfolio benefits? The two AI stocks below are for you. Nvidia remains the smartest AI investment When it comes to AI stocks, Nvidia (NASDAQ: NVDA) is king. Even if you're already familiar with this stock, there's a good chance that shares are much cheaper than you realize. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » If you've been following the AI market, you'll know that Nvidia is the most valuable GPU maker in the world. GPUs sit at the heart of the AI revolution. They're critical for training and deploying complex AI models. They also make it possible for end users to access these models en masse from anywhere in the world. Right now, Nvidia's GPUs dominate the market. The firm has an estimated 90% market share for AI GPUs. Its performance and ecosystem advantages have granted the company the highest gross margins in the industry. Wall Street analysts are unsurprisingly excited. Wedbush Securities analyst Dan Ives believes Nvidia's market cap will surge to $5 trillion within months. The biggest near-term catalyst: the decision by the U.S. government to allow Nvidia's new GPUs to be exported to China, a country that previously accounted for around 13% of the company's sales. While shares are expensive based on trailing earnings, the stock trades at just 39 times forward earnings. Considering the AI boom is expected to persist for a decade or more, expect Nvidia to maintain double-digit annual growth rates for years to come. This should quickly eat into the upfront valuation premium, making shares a relative bargain for patient investors. Amazon is an artificial intelligence powerhouse Apart from Nvidia, Amazon (NASDAQ: AMZN) stock looks like one of the best ways to invest in the AI revolution over the long term. That's because its most profitable business segment, Amazon Web Services, sits at the center of everything AI. We've already discussed how Nvidia's GPUs sit between AI developers and the end users themselves. But there's one other industry that also sits at the center of the action: cloud infrastructure providers. Most estimates believe Amazon's AWS division is the largest cloud infrastructure provider in the world. Data compiled by Statista gives AWS a 30% global market share, nearly as much as the next two competitors combined. While the data center industry is a bit more commoditized than the GPU market, there's clear differentiation by the players that can afford to invest at scale. Developers -- AI developers in particular -- want the best infrastructure possible. That includes the best hardware and the most locations from a geographic perspective. This makes it quicker, cheaper, and more convenient for customers. As the largest cloud provider in the world, Amazon is second to none in its ability to invest and expand its network. This should continue to place AWS at the center of increased spending. "Companies are spending and they're spending more, and they plan to spend even more," Baird analyst Colin Sebastian recently told GeekWire. "We did a survey last month of 100 corporations, and 87% of them said they will increase spending on Gen AI over the next year -- and a grand total of zero out of 100 said they would spend less." The AI spending boom is real. Demand should grow by 20% to 30% annually for years to come. With Amazon trading at 37 times earnings, most of its growth in this area is masked by its relatively slower growing e-commerce division. But as AWS becomes a bigger driver of Amazon's overall business, we could see growth rates accelerate, making shares a relative bargain in hindsight. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
